Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
236 USD | -0.44% | -0.41% | +7.30% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 9.89 for the current year and 9.63 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.30% | 11.15B | B+ | ||
+1.12% | 43.84B | B | ||
+6.77% | 41.68B | B- | ||
+45.26% | 41.25B | A | ||
-11.96% | 27.04B | C | ||
+6.01% | 25.53B | B- | ||
-24.92% | 18.18B | B | ||
-3.63% | 12.29B | C+ | ||
+27.16% | 12.29B | C+ | ||
-18.79% | 9.98B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UTHR Stock
- Ratings United Therapeutics Corporation